Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) announced its participation in two key investor conferences in September 2022. The first is the H.C. Wainwright 24th Annual Global Investment Conference, where a virtual fireside chat will occur from September 12-14. A recording will be available for 90 days. The second event is the Jefferies Innovation in Mental Health Summit on September 22, also featuring a fireside chat. Reunion focuses on developing innovative psychedelic-inspired therapies for mental health, including its lead compound, RE-104, targeting postpartum and treatment-resistant depression.
Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) announced its 2022 Annual General Meeting (AGM) scheduled for September 29, 2022, at 10:00 AM ET. Shareholders of record as of August 23, 2022, can vote and ask questions online. The AGM will be accessible virtually, and registration is required for teleconference dial-in. Key documents, including the Notice of Meeting and Management Information Circular, are available on SEDAR and EDGAR. Reunion focuses on innovative psychedelic therapeutics for mental health, including its lead asset, RE-104, aimed at treating post-partum depression.